The Emerging Role of Neuropeptides in Parkinson’s Disease

Frontiers in Aging Neuroscience

Linlin Zhang¹  Yanan Zheng¹  Junxia Xie²  Limin Shi² 

[1] Department of Physiology, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, School of Basic Medicine, Qingdao University, Qingdao, China;Institute of Brain Science and Disease, Qingdao University, Qingdao, China;

关键词: Parkinson’s disease;    neuropeptides;    ghrelin;    neuropeptide Y;    pituitary adenylate cyclase-activating polypeptide;    substance P;   

DOI  :  10.3389/fnagi.2021.646726

来源: DOAJ

【 摘 要 】

Parkinson’s disease (PD), the second most common age-related neurodegenerative disease, results from the loss of dopamine neurons in the substantia nigra. This disease is characterized by cardinal non-motor and motor symptoms. Several studies have demonstrated that neuropeptides, such as ghrelin, neuropeptide Y, pituitary adenylate cyclase-activating polypeptide, substance P, and neurotensin, are related to the onset of PD. This review mainly describes the changes in these neuropeptides and their receptors in the substantia nigra-striatum system as well as the other PD-related brain regions. Based on several in vitro and in vivo studies, most neuropeptides play a significant neuroprotective role in PD by preventing caspase-3 activation, decreasing mitochondrial-related oxidative stress, increasing mitochondrial biogenesis, inhibiting microglial activation, and anti-autophagic activity. Thus, neuropeptides may provide a new strategy for PD therapy.

【 授权许可】

Unknown